Drugs / 64Cu-LLP2A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06636175 | Mar 2025 → Mar 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma +1 | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT03804424 | Nov 2018 → Oct 2021 | plasma cell myeloma | Washington University School of Medicine | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-LLP2A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06636175 ↗ |
| Modality | Diagnostic / imaging agent | “64Cu-LLP2A-positron emission tomography (PET)/magnetic resonance (MR)” NCT03804424 ↗ |